Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Solid Biosciences Inc. (SLDB)

7.64   0.19 (2.55%) 01-27 16:00
Open: 7.47 Pre. Close: 7.45
High: 7.85 Low: 7.37
Volume: 27,263 Market Cap: 149(M)

Technical analysis

as of: 2023-01-27 4:48:00 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 9.16     One year: 10.7
Support: Support1: 6.21    Support2: 5.21
Resistance: Resistance1: 7.84    Resistance2: 9.16
Pivot: 6.87
Moving Average: MA(5): 7.41     MA(20): 6.57
MA(100): 6.98     MA(250): 9.8
MACD: MACD(12,26): 0.3     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 92.6     %D(3): 92.3
RSI: RSI(14): 69.1
52-week: High: 21.45  Low: 0.51
Average Vol(K): 3-Month: 30 (K)  10-Days: 37 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SLDB ] has closed below upper band by 17.5%. Bollinger Bands are 45.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.86 - 7.89 7.89 - 7.92
Low: 7.29 - 7.33 7.33 - 7.36
Close: 7.58 - 7.64 7.64 - 7.69

Company Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 26 Jan 2023
$SLDB Solid Biosciences Inc Files For Resale Of Up To About 12 ... - CML News

Thu, 26 Jan 2023
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy - Yahoo Finance

Wed, 25 Jan 2023
Government of Saint Lucia Advances National Readiness to Access ... - The Voice St. Lucia

Tue, 17 Jan 2023
Is it Time to Dump Solid Biosciences Inc (SLDB) Stock After it Has Gained 21.67% in a Week? - InvestorsObserver

Tue, 10 Jan 2023
Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases - Yahoo Finance

Mon, 05 Dec 2022
Solid Biosciences Announces Closing of Acquisition of AavantiBio ... - Solid Biosciences

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 20 (M)
Shares Float 3 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 69.1 (%)
Shares Short 77 (K)
Shares Short P.Month 110 (K)

Stock Financials

EPS -0.73
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 19.02
Profit Margin (%) 0
Operating Margin (%) -791.5
Return on Assets (ttm) -25.7
Return on Equity (ttm) -48.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.69
Sales Per Share 0.57
EBITDA (p.s.) -4.43
Qtrly Earnings Growth 0
Operating Cash Flow -84 (M)
Levered Free Cash Flow -48 (M)

Stock Valuations

PE Ratio -10.62
PEG Ratio 0
Price to Book value 0.4
Price to Sales 13.26
Price to Cash Flow -1.77

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.